Print

Cross-sectional Group Sessions

 

If your interests are not easily defined by just one section, consider these Cross-sectional platform sessions.

Sunday, May 1, 2:45-4:15pm MT

AI based imaging biomarker: New updates and real-world implementation (MOI)
Organizer: Carol Cheung
Speakers: Ursula Schmidt-Erfuth, Yali Jia, Michael D. Abramoff, Aaron Lee, Carol Y. Cheung, Pearse Keane and Tien Y. Wong

World-renowned experts will share the latest development in the field of AI-based imaging biomarker, and the foundational considerations, opportunities, lessons and challenges for integrating AI into the clinical care pathways.


Monday, May 2, 10-11:30am MT

Spotlight on macular disease: Impact on everyday function and wellbeing (LV)
Organizers: Alex Black, Ruth van Nispen and Aurelie Calabrese
Speakers: Joanne Wood, Susana Chung, Robert Finger and Hilde van Der Aa

This session will provide an overview of current research on the impact of macular disease on everyday function and wellbeing. This session will include presentations on a number of everyday functions and how it impacts on people with macular disease, including driving, reading, patient-reported outcomes, face recognition, and mental health.


Tuesday, May 3, 1-2:30pm MT

Gene editing technologies: From basic understanding of ocular development and inherited disease to novel therapeutic approaches (GEN)
Organizers: Alice Davidson, Sudha Iyengar and Pirro Hysi
Speakers: Bruce Conklin, Joe Rainger, Krzysztof Palczewski, Tara Moore and Mark Pennesi

Gene editing technologies have led to significant advances in our understanding of ocular development and mechanisms of inherited ophthalmic disease. This cross-sectional GEN session comprises a diverse range of leading experts in the field with significant experience and expertise in utilizing gene-editing technologies. The session will highlight how these tools have advanced our understanding of ocular development and inherited disease mechanisms, in addition to showcasing gene-editing based therapies under development to treat inherited ocular disease.